Mar 04, 2021 09:12 JST

Source: Eisai

Eisai to Support Construction of Screening Framework for the Novel Coronavirus Infection in Kenya

TOKYO, Mar 04, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has decided to assent to and support a project led by CA Medlynks Kenya, Ltd., a subsidiary of the healthcare startup company engaged in improving healthcare access in Africa, Connect Afya Co., Ltd., which aims to build a new structure for the efficient testing framework for the novel coronavirus infection in Kenya. CA Medlynks Kenya, Ltd., in collaboration with the government of Meru County in Kenya, will support the setup of PCR testing laboratories, along with procurement of equipment necessary for testing and training of screening technicians.

Meru County, one of Kenya's 47 counties, is the most populous county in the Eastern Province of Kenya with approximately 1.35 million people. As the novel coronavirus infection spreads in Kenya, one issue in Meru County is the time required to receive screening results as samples must be sent across over 200 kilometers to the capital city of Nairobi for testing, a situation which is caused by a lack of equipment, facilities and technicians necessary for screening of the novel coronavirus. It is expected that support for this effort will contribute largely to the formation of accurate and rapid understanding of the infection situation as well as strategy that is based on that understanding by construction of PCR testing in Meru County.

Eisai has committed the equivalent of 1 million USD in aid over the span of 1 year in order to support the controlling of the spread of the novel coronavirus infection in Africa, along with prevention of delays of elimination activities for neglected tropical diseases (NTDs). As part of this support, Eisai has begun provision of Personal Protection Equipment (masks, goggles, face shields, etc.) to core hospitals in Africa for research of and countermeasures against infectious diseases, as well as masks and sanitizer for the resuming of mass drug administrations in Kenya for the elimination of NTDs. In addition, Eisai is supporting Amref Health Africa in the development and popularization of its mobile health platform LEAP for healthcare workers in sub-Saharan countries.

Through this support, including the new support for Connect Afya, Eisai will continue in its contribution to mitigating the spread of the novel coronavirus infection in Kenya and other African countries.

About Connect Afya Co., Ltd. and CA Medlynks Kenya, Ltd.

Connect Afya Co., Ltd. (Headquarters: Hyogo, Japan, CEO: Yoichi Shimada) and its local affiliate CA Medlynks Kenya Ltd. (Location: Nairobi are startups delivering clinical laboratory services and providing in-vitro diagnostic medical equipment, for the realization of a society where people enjoy better lives without suffering from limitations of insufficient medical infrastructure.

As of February 2021, the startup has supplied diagnostic services and in-vitro diagnostic medical equipment, including novel coronavirus infection reverse transcription PCR screening equipment, to over thirty healthcare organizations, clinics, and corporations across Kenya.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
September 17 2025 17:20 JST
 
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
September 12 2025 12:20 JST
 
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
September 08 2025 16:49 JST
 
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
September 04 2025 09:56 JST
 
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
September 03 2025 10:32 JST
 
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
September 01 2025 12:44 JST
 
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
August 29 2025 17:17 JST
 
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
August 25 2025 18:30 JST
 
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
August 18 2025 08:11 JST
 
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31 2025 17:27 JST
 
More Press release >>

Latest Press Release


More Latest Release >>